Journal ArticleDOI
Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease—a single center case series
Efrat Luttwak,Efrat Luttwak,David Hagin,David Hagin,Chava Perry,Chava Perry,Ofir Wolach,Ofir Wolach,Gilad Itchaki,Gilad Itchaki,Odelia Amit,Odelia Amit,Yael Bar-On,Yael Bar-On,Tal Freund,Tal Freund,Sigi Kay,Sigi Kay,Rinat Eshel,Rinat Eshel,Irit Avivi,Irit Avivi,Ron Ram,Ron Ram +23 more
TLDR
This is the first report demonstrating that patients with EBV-negative refractory PTLD may benefit from CAR-T therapy, similarly to other patients with relapse/refractory DLBCL.Abstract:
Posttransplantation lymphoproliferative disease (PTLD) is a potentially fatal disorder arising after solid organ or hematopoietic cell transplantation. Survival rates of PTLD with diffuse large B-cell lymphoma (DLBCL) phenotype have improved due to the introduction of rituximab, however, reports on curative management of refractory PTLD are scarce. Here, we describe successful management of three patients with refractory EBV-negative PTLD with chimeric antigen receptor T-cell (CAR-T) therapy. All patients continued calcineurin inhibitors throughout the whole course of treatment. T-cell immunophenotyping was performed on both the apheresed cells and CAR-T product to investigate the T-cell compartment subpopulations. All three patients responded to a single infusion of tisagenlecleucel and two of them achieved CR. Toxicity profile was similar to other patients with non-PTLD DLBCL treated with CAR-T. No transplanted graft dysfunction was observed during the course of therapy. To our knowledge, this is the first report demonstrating that patients with EBV-negative refractory PTLD may benefit from CAR-T therapy, similarly to other patients with relapse/refractory DLBCL. A larger cohort of patients is needed to further establish proof-of-concept.read more
Citations
More filters
Journal ArticleDOI
CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review.
Rafael Hernani,Asunción Sancho,Paula Amat,Juan Carlos Hernández-Boluda,Ariadna Pérez,José Luis Piñana,Carlos Carretero,Rosa Goterris,Montse Gómez,Ana Saus,Blanca Ferrer,Ana Isabel Teruel,María José Terol,Carlos Solano +13 more
TL;DR: In this paper, the authors describe the clinical outcome in one PTLD patient and propose a strategy for tailoring immunosuppressive treatment and organ monitoring in patients with kidney allografts after CAR-T infusion.
Journal ArticleDOI
Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review
TL;DR: In this article, a post-transplant lymphoproliferative disease (PTLD) patient with a high tumor burden was enrolled in a clinical trial of anti-CD19-CAR T-cell therapy.
Journal ArticleDOI
Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation
Francesco Pegoraro,Claudio Favre +1 more
TL;DR: In this paper, a post-transplantation lymphoproliferative disorder (PTLD) is a severe complication of haematopoietic stem cell transplantation (HSCT), occurring in a setting of immune suppression and dysregulation.
Journal ArticleDOI
CAR T-cell Infusion Following Checkpoint Inhibition Can Induce Remission in Chemorefractory Post-transplant Lymphoproliferative Disorder of the CNS
Wiebke Rösler,Andrea Bink,Marina Bissig,Lukas L. Imbach,Ewerton Marques Maggio,Markus G. Manz,T. Müller,Patrick Roth,Elisabeth J. Rushing,Corinne C Widmer,Thorsten Zenz,Seraina von Moos,Antonia M.S. Müller +12 more
TL;DR: In this paper , the authors presented the successful treatment of a patient with post-transplant lymphoproliferative disorder (PTLD) with checkpoint inhibition, followed by infusion of chimeric antigen receptor T cells (CAR-T).
References
More filters
Journal ArticleDOI
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee,Bianca Santomasso,Frederick L. Locke,Armin Ghobadi,Cameron J. Turtle,Jennifer N. Brudno,Marcela V. Maus,Jae H. Park,Elena Mead,Steven Z. Pavletic,William Y. Go,Lamis K. Eldjerou,Rebecca Gardner,Noelle V. Frey,Kevin J. Curran,Karl S. Peggs,Marcelo C. Pasquini,John F. DiPersio,Marcel R.M. van den Brink,Krishna V. Komanduri,Stephan A. Grupp,Sattva S. Neelapu +21 more
TL;DR: The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting.
Journal ArticleDOI
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno,Robert Somerville,Victoria Shi,Jeremy J. Rose,David Halverson,Daniel H. Fowler,Juan C. Gea-Banacloche,Steven Z. Pavletic,Dennis D. Hickstein,Tangying L. Lu,Steven A. Feldman,Alexander T. Iwamoto,Roger Kurlander,Irina Maric,Andre Goy,Brenna G. Hansen,Jennifer S. Wilder,Bazetta Blacklock-Schuver,Frances T. Hakim,Steven A. Rosenberg,R. E. Gress,James N. Kochenderfer +21 more
TL;DR: Allogeneic anti-CD19 CAR T cells can effectively treat B-cell malignancies that progress after alloHSCT, and the findings point toward a future when antigen-specific T-cell therapies will play a central role in allo HSCT.
ASBMT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
DW Lee,Bianca Santomasso,Frederick L. Locke,Armin Ghobadi,Cameron J. Turtle,Jennifer N. Brudno,Marcela V. Maus,JH Park,Elena Mead,Steven Z. Pavletic,WY Go,Lamis K. Eldjerou,Rebecca Gardner,Noelle V. Frey,Kevin J. Curran,Karl S. Peggs,Marcelo C. Pasquini,John F. DiPersio,Mrm van den Brink,Krishna V. Komanduri,Stephan A. Grupp,Sattva S. Neelapu +21 more
TL;DR: In 2018, the American Society for Blood and Marrow Transplantation (ASBMT) recognized the need to harmonize the definitions and grading systems for cytokine release syndrome (CRS) and neurotoxicity associated with CAR T cell therapies.
Journal ArticleDOI
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.
TL;DR: Multiple myeloma accounts for approximately 10% of hematologic malignancies in the United States and is the second most common cancer in women.
Journal ArticleDOI
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
Conrad Russell Y. Cruz,Kenneth P. Micklethwaite,Barbara Savoldo,Carlos A. Ramos,Sharon Lam,Stephanie Ku,Oumar Diouf,Enli Liu,A. John Barrett,Sawa Ito,Elizabeth J. Shpall,Robert A. Krance,Robert A. Krance,Rammurti T. Kamble,Rammurti T. Kamble,George Carrum,George Carrum,Chitra Hosing,Adrian P. Gee,Zhuyong Mei,Bambi Grilley,Helen E. Heslop,Helen E. Heslop,Cliona M. Rooney,Malcolm K. Brenner,Malcolm K. Brenner,Catherine M. Bollard,Catherine M. Bollard,Gianpietro Dotti +28 more
TL;DR: CD19.CAR-VSTs display antitumor activity and, because their number may be increased in the presence of viral stimuli, earlier treatment post-HSCT (when lymphodepletion is greater and the incidence of viral infection is higher) or planned vaccination with viral antigens may enhance disease control.